Optimizing outcomes for patients with metastatic prostate cancer: insights from South East Asia Expert Panel.

Ther Adv Med Oncol · 2021 · PMC7905487 · PMID 33747148

Europe PMC DOI

hedged sentence

0.0100

closest p · 0.2× alpha

0.0100

boldest claim

The sentences

showed a trendp = 0.01actually significant

When compared with placebo, abiraterone improved radiographic PFS (8.3 months versus 16.5 months; HR: 0.53; 95% CI: 0.45–0.62; p < 0.001) and showed a trend towards improved OS (27.2 months versus not reached; HR: 0.75; 95% CI: 0.61–0.93; p = 0.01).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.